Pradaxa (dabigatrani etexilati mesilas) belongs to a new group of anticoagulants, its pharmacological properties enabling uniform dosage without a need for monitoring the anticoagulant effect. It is an oral direct thrombin inhibitor. Pradaxa is the first NOAC (new oral anticoagulant) with a specific reversal agent called Praxbind (idarucizumab). Dabigatran is indicated for the prophylaxis of venous thromboembolism in elective hip or knee replacements, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis and pulmonary embolism and also their recurrence in adult patients.Key words: dabigatrani etexilati anticoagulant therapy - thromboembolism idarucizumab.

• MeSH
• akutní bolest břicha * etiologie   MeSH
• antikoagulancia * škodlivé účinky   MeSH
• antitrombiny MeSH
• dabigatran * škodlivé účinky   MeSH
• dospělí MeSH
• krvácení chemicky indukované   MeSH
• lidé MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• antikoagulancia * MeSH
• antitrombiny MeSH
• dabigatran * MeSH